Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticancer agents and cardiotoxicity.

Raymond Ng1, Nathan Better, Michael D Green

  • 1Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Seminars in Oncology
|February 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence (AI) psychosis: mechanisms, clinical risks and safety considerations in generative AI chatbots.

BJPsych open·2026
Same author

A Chatbot for the Management of Bipolar Disorder: Using Retrieval-Augmented Generation With an Open-Weight Large Language Model to Answer Clinical Questions Based on the CANMAT and ISBD 2018 Guidelines for Bipolar Disorder: Un dialogueur pour la prise en charge du trouble bipolaire : utiliser la génération augmentée par récupération avec un grand modèle de langage (GML) à poids ouverts pour répondre aux questions cliniques fondées sur les lignes directrices de 2018 de CANMAT et de l'ISBD relatives au trouble bipolaire.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same author

Strategies for mitigating artificial intelligence bias in healthcare: a systematic review.

JAMIA open·2026
Same author

Polygenic risk scores for prediction of immune checkpoint inhibitor thyroid toxicity in diverse populations.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Racial and ethnic diversity in clinical studies reported to ClinicalTrials.gov, 2009-2024.

BMJ open quality·2026
Same author

Cardiac amyloid radionuclide imaging: Global perspective and future priorities.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026

Cancer treatments like anthracyclines can cause heart damage (cardiotoxicity). Monitoring left ventricular ejection fraction (LVEF) is crucial for managing this risk in patients undergoing cancer therapy.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Cardiotoxicity is a serious complication of cancer treatment, influenced by drug type, dose, patient age, and prior treatments.
  • Anthracyclines, while effective, are limited by cumulative dose-dependent cardiotoxicity.
  • Newer agents like taxanes and trastuzumab also contribute to cardiotoxicity, particularly in metastatic breast cancer.

Purpose of the Study:

  • To review the incidence, risk factors, and management strategies for cardiotoxicity in cancer patients.
  • To highlight the importance of monitoring cardiac function during and after cancer therapy.

Main Methods:

  • Literature review of cardiotoxicity associated with common cancer chemotherapeutics.
  • Discussion of current monitoring techniques, including two-dimensional echocardiography and radionuclide ventriculography.

Related Experiment Videos

  • Overview of cardioprotective strategies and novel drug formulations.

    • Main Results:

    • Cardiotoxicity risk is multifactorial, involving drug specifics, patient comorbidities, and treatment history.
    • Left ventricular ejection fraction (LVEF) assessment is a practical method for monitoring cardiac function.
    • Cardioprotective agents (e.g., dexrazoxane) and modified drug delivery (e.g., liposomal formulations) can mitigate risks.

    Conclusions:

    • Cardiotoxicity remains a significant clinical challenge, especially with increasing long-term cancer survivor rates.
    • Proactive cardiac monitoring and risk mitigation strategies are essential for patients receiving cardiotoxic cancer therapies.
    • The management of cardiotoxicity is critical for improving outcomes in both pediatric and adult cancer survivors.